Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
174 studies found for:    "PDGFRA-associated chronic eosinophilic leukemia" OR "Hypereosinophilic Syndrome"
Show Display Options
Download search resultsDownload the search results for:
"PDGFRA-associated chronic eosinophilic leukemia" OR "Hypereosinophilic Syndrome" (174 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Terminated A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: imatinib mesylate
2 Recruiting Compassionate Use of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES)
Condition: Hypereosinophilic Syndrome
Intervention: Drug: mepolizumab
3 Completed Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: SCH55700
4 Terminated
Has Results
Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: mepolizumab
5 Not yet recruiting Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
Condition: Hypereosinophilic Syndrome
Interventions: Drug: Mepolizumab 300 mg;   Drug: Placebo matching mepolizumab;   Drug: Active OCS capsules (5 mg prednisolone or prednisone);   Drug: Placebo matching OCS capsules
6 Recruiting Imatinib Mesylate to Treat Myeloproliferative Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: Imatinib Mesylate
7 Active, not recruiting Identification of New Markers in the Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Biological: biologie sample
8 Recruiting Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: Dexpramipexole
9 Recruiting Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Interventions: Drug: benralizumab;   Other: Placebo
10 Completed Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes
Conditions: Hypereosinophilic Syndrome;   Chronic Eosinophilic Leukemia;   Chronic Idiopathic Hypereosinophilia
Intervention: Drug: Imatinib
11 Completed Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
Conditions: Hypereosinophilia;   Hypereosinophilic Syndrome
Intervention: Drug: mepolizumab
12 Unknown  Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias
Conditions: Hypereosinophilic Syndrome;   Chronic Eosinophilic Leukemia (CEL);   Myeloproliferative Disorders
Intervention: Drug: STI571
13 Withdrawn Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
Conditions: Eosinophilia;   Hypereosinophilic Syndrome
Intervention: Drug: Gleevec
14 Recruiting Eosinophilia Diagnosis
Condition: Hypereosinophilic Syndrome
Intervention: Other: Scheduled exams and diagnosis
15 Recruiting Steroid Treatment for Hypereosinophilic Syndrome
Condition: Hypereosinophilia
Intervention: Drug: Corticosteroids
16 Completed 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
Condition: Leukemia
Interventions: Drug: 2-CdA;   Drug: Ara-C;   Drug: G-CSF (Granulocyte colony-stimulating factor)
17 Completed Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
Conditions: Hypereosinophilic Syndromes;   Eosinophilic Gastroenteritis;   Churg-Strauss Syndrome;   Eosinophilic Esophagitis
Intervention: Drug: Mepolizumab
18 Completed Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
Conditions: Chronic Myelomonocytic Leukemia;   Chronic Myeloid Leukemia;   Polycythemia Vera;   Hypereosinophilic Syndrome;   Mastocytosis
Intervention: Drug: Imatinib Mesylate (Gleevec)
19 Active, not recruiting Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Agnogenic Myeloid Metaplasia;   Myelofibrosis;   Hypereosinophilic Syndrome;   Polycythemia Vera;   Mastocytosis;   Leukemia, Myelomonocytic, Chronic
Intervention: Drug: Dasatinib (BMS-354825)
20 Completed Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Conditions: Hypereosinophilic Syndrome;   Systemic Mastocytosis;   Chronic Myelomonocytic Leukemia;   Dermatofibrosarcoma
Intervention: Drug: imatinib mesylate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.